247wallst.com · 9 jul

Jim Cramer Says Biotech is The Hottest Group in The Market Right Now

CNBC's Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter.

barrons.com · 9 jul

AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.

AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing drug, Wainua.

zacks.com · 6 jul

Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?

ALNY's advancing pipeline and partnered programs can expand future revenue sources alongside its growing portfolio of approved therapies.

fool.com · 2 jul

Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.

The company has six marketed therapies and several others in late-stage clinical trials. Alnylam has a unique drug delivery system that gives it a deeper moat.

seekingalpha.com · 25 jun

Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding Disorders Transcript

Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding Disorders Transcript

businesswire.com · 25 jun

Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform

NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Komodo Health®, the leader in AI-powered healthcare intelligence, today announced an expanded strategic partnership with Alnylam Pharmaceuticals (Nasdaq: ALNY), the leading RNAi therapeutics company to scale Marmot™, Komodo's analytics AI platform, across key enterprise functions at Alnylam. Built on the Healthcare Map®, the industry's most comprehensive view of more than 330 million de-identified patient journeys, Marmot helps organizations move beyon.

zacks.com · 22 jun

Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?

Amvuttra is the primary driver of ALNY's revenues, but growth from Givlaari, Oxlumo and Leqvio may help diversify the company's top line.

forbes.com · 17 jun

The Healthcare M&A Wave

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.